In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Select congresses

    Select Select congresses(s)

  • Year

    Select Year(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • Select congresses
  • sub-topic
  • Year
  • Resource type
  • Topic
  • Select congresses
  • sub-topic
  • Year
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Vifor Pharma

80 results for your search

The ESC 2016 Heart Failure Guidelines: what is the recommendation for iron deficiency and why?

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Implementation of guidelines – Practicalities of giving intravenous (IV) iron.

Event : EuroHeartCare 2018

  • Session : Iron deficiency and heart health
  • Speaker : N Caples (Waterford,IE)
  • Sponsored by Vifor Pharma UK Ltd

Iron deficiency: an important comorbidity - Welcome.

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Vifor Pharma

Managing iron deficiency: a practical approach.

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : CS Lam (Singapore,SG)
  • Sponsored by Vifor Pharma

Practical implementation of The ESC 2016 Heart Failure Guidelines: management of iron deficiency - Conclusion.

Event : Heart Failure 2018

  • Session : Practical implementation of The ESC 2016 Heart Failure Guidelines: management of iron deficiency
  • Speaker : M Boehm (Homburg,DE)
  • Sponsored by Vifor Pharma

Panel discussion.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Introduction

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Vifor Pharma

Changing the treatment paradigm of hyperkalaemia management to enable and optimize renin-angiotensin-aldosterone system inhibitors therapy.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Clinical case discussion.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : J Comin-Colet (Hospitalet De Llobregat,ES), J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma

Introduction - Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are